Skip to content
Resources > Reports

AI in Drug Development 2026: From Experimentation to Execution

By Sara Mallatt, Director of Healthcare Research and Sean Carmichael, Senior Business & Finance Editor

AI has advanced from pilot programs into real biopharma workflows. But has it lived up to the hype? Drawing from an expert call with Dr. Paul Agapow, former director of data science at GSK, this report dissects whether AI is on track to make drug development faster, cheaper, and more successful. Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.

About the Authors
  • Sara Mallatt

    Sara Mallatt, Director of Healthcare Research

    Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.
  • Sean Carmichael

    Sean Carmichael, Senior Business & Finance Editor

    Sean is a Senior Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.

Explore more

AI in 2027: Turning Capability Into Value

In 2027, realizing AI’s potential will depend on organizational choices: how much authority agents receive, what information they remember, and how people develop the expertise to oversee them.
Blue graphic with text reading "AI in 2027: Turning Capability Into Value" by Sarah Hoffman, featuring line-art icons of a data dashboard, shipping boxes, and a security shield.

How SuperAnalyst Surfaces M&A Intelligence

In this report, discover how SuperAnalyst from AlphaSense surfaces the facts, figures, and expert perspectives behind 2026’s defining M&A trends: mega deals, creative PE exits, AI as a deal catalyst, sector consolidation, and what it all means for 2027.
Graphic titled "How SuperAnalyst Surfaces M&A Intelligence" by Barb Tague, featuring a blue grid, curved wireframe geometric shape, and two puzzle pieces on a navy blue background.

How Family Offices Are Leveraging Trusted AI at Scale

While AI adoption is widespread among institutional investors, only 22% of family offices use AI with regularity. Data privacy and trustability largely remain barriers to adoption.
How Family Offices Are Leveraging Trusted AI, with an isometric line drawing of an office desk and chair.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.